Heat treatment after polyp removal may slash regrowth risk
NCT ID NCT07242820
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests whether adding a heat treatment (thermal ablation) to the standard procedure for removing large colon polyps can lower the chance they grow back. About 752 adults will be randomly assigned to receive either standard removal alone or standard removal plus burning of the edges and base of the site. Participants will be followed for 18 months with two follow-up colonoscopies to check for recurrence and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- adjuvant thermal ablation (a procedure that uses heat to burn the edges and base of the polyp removal site)
- What this could lead to
- If it works, this could become a standard step during colonoscopy to reduce the chance that large polyps grow back.
- What could go wrong
- This is a relatively early-stage procedure comparison, not a new drug. The benefit may be small, and there is a risk of bleeding or perforation from the extra burning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 752 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients * Undergoing EMR for large (≥20 mm) colorectal LSL * Providing written and informed consent for study participation Exclusion Criteria: * Inflammatory bowel disease * Non-elective colonoscopy * Poor general health (American Society of Anesthesiologists classification \>III) * Coagulopathy or thrombocytopenia (international normalized ration ≥1.5 or platelets \<50\*10\^9/L) * Bulky lesions (granular mixed with ≥10mm module).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers